David Chang, PhD
Hematology & Oncology · Newport News, VANPI 1982718078
Payments from drug & device makers
Across 212 payments — averaging $5545.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$485K
- E.r. Squibb & Sons, L.L.C.$288K
- Bayer$243K
- AstraZeneca$93K
- Ipsen Bioscience Inc.$20K
- Beone Medicines USA, Inc.$13K
- plus $35K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $484,566 |
| E.r. Squibb & Sons, L.L.C. | 14 | $287,914 |
| Bayer | 38 | $242,697 |
| AstraZeneca | 60 | $92,515 |
| Ipsen Bioscience Inc. | 10 | $20,000 |
| Beone Medicines USA, Inc. | 7 | $12,884 |
| Exelixis Inc. | 12 | $7,172 |
| Taiho Oncology, Inc. | 3 | $5,763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $5,198 |
| Seagen Inc. | 6 | $3,500 |
| G1 Therapeutics, Inc. | 2 | $3,000 |
| Beigene USA, Inc. | 7 | $2,186 |
| Ipsen Biopharmaceuticals, Inc | 3 | $1,791 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Incyte Corporation | 2 | $1,461 |
| Coherus Oncology, Inc. | 1 | $1,350 |
| Amgen | 3 | $1,067 |
| Conmed Corporation | 3 | $189 |
| Eisai Inc. | 2 | $170 |
| Array Biopharma Inc | 1 | $150 |
| EMD Serono, Inc. | 1 | $106 |
| Medtronic | 1 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Chiesi USA, Inc. | 1 | $84 |
| SPR Therapeutics, Inc | 1 | $35 |
| AbbVie | 1 | $18 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $4 |
How this compares
$1,175,584 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Newport News
- Graham WatsonNewport News$779K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.